Literature DB >> 21235898

Ischemia-driven angiogenesis.

Y Dor1, E Keshet.   

Abstract

New blood vessels usually develop in places where they are most needed. A prime example of neovascularization representing a positive feedback response to insufficient perfusion is the development of collateral blood vessels in the ischemic myocardium and leg. The recent discoveries of hypoxia-inducible transcription and angiogenic factors have provided important mechanistic links between the metabolic consequences of ischemia and compensatory angiogenesis. Vascular endothelial growth factor (VEGF) has emerged as the key mediator of ischemia-driven angiogenesis. Environmental stresses, including hypoxia, hypoglycemia, and hypoferremia, upregulate VEGF expression at both the transcriptional and posttranscriptional levels. VEGF acts in turn on adjacent vascular beds expressing cognate receptors and induces sprouting and capillary growth toward the ischemic tissue. In addition to expanding the vasculature at sites where existing vessels have been occluded or obliterated, VEGF also functions to match the vascular density according to development and physiologic increases in oxygen consumption. Fine adjustment of the vasculature includes a step of oxygen-regulated vascular pruning mediated by VEGF in its capacity as a survival factor for newly formed vessels. Pathologic settings of ischemia-driven angiogenesis include a major component of stress-induced angiogenesis during tumor neovascularization and abnormal vessel growth associated with retinopathies. The latter represents an excessive angiogenic response to conditions of severe retinal ischemia. Further insights into the mechanism of stress-induced angiogenesis are likely to suggest new ways to augment growth of collateral vessels and to restrain unwarranted neovascularization in tumors and retinopathies. (Trends Cardiovasc Med 1997;7:289-294). © 1997, Elsevier Science Inc.
Copyright © 1997 Elsevier Science Inc. All rights reserved.

Entities:  

Year:  1997        PMID: 21235898     DOI: 10.1016/S1050-1738(97)00091-1

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  11 in total

Review 1.  Glucose, VEGF-A, and diabetic complications.

Authors:  L E Benjamin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Chorangiocarcinoma: a case report and clinical review.

Authors:  Bin Huang; Yan-Ping Zhang; Dan-Fang Yuan; Rui Yang; Chun Wang; Rui-Fang Wu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization.

Authors:  Alexander V Ljubimov; Sergio Caballero; Annette M Aoki; Lorenzo A Pinna; Maria B Grant; Raquel Castellon
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

4.  VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain.

Authors:  N van Bruggen; H Thibodeaux; J T Palmer; W P Lee; L Fu; B Cairns; D Tumas; R Gerlai; S P Williams; M van Lookeren Campagne; N Ferrara
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

5.  Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy.

Authors:  Yuval Dor; Valentin Djonov; Rinat Abramovitch; Ahuva Itin; Glenn I Fishman; Peter Carmeliet; Gadi Goelman; Eli Keshet
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

6.  "Imaging Evaluation of Collaterals in the Brain: Physiology and Clinical Translation"

Authors:  Sunil A Sheth; David S Liebeskind
Journal:  Curr Radiol Rep       Date:  2014-01

Review 7.  New advances in targeted gastric cancer treatment.

Authors:  Daniela Cornelia Lazăr; Sorina Tăban; Marioara Cornianu; Alexandra Faur; Adrian Goldiş
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

8.  Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye.

Authors:  Hu Huang; Jikui Shen; Stanley A Vinores
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

Review 9.  Adenosine kinase: An epigenetic modulator in development and disease.

Authors:  Madhuvika Murugan; Denise Fedele; David Millner; Enmar Alharfoush; Geetasravya Vegunta; Detlev Boison
Journal:  Neurochem Int       Date:  2021-05-05       Impact factor: 4.297

Review 10.  Neurorestorative therapy for stroke.

Authors:  Jieli Chen; Poornima Venkat; Alex Zacharek; Michael Chopp
Journal:  Front Hum Neurosci       Date:  2014-06-27       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.